Antagonists of TNF action: clinical experience and new developments
Authors:
- Roland E KontermannRKRoland E Kontermann
- Peter ScheurichPSPeter Scheurich
- Klaus PfizenmaierKPKlaus Pfizenmaier
- 8 March 2009
- journal article
- Published by Taylor & Francis in Expert Opinion on Drug Discovery
- Vol. 4 (3) , 279-292
Abstract
Background: TNF is a central mediator of inflammation and key target for intervention in inflammatory diseases such as rheumatoid arthritis, psoriasis and Crohn's disease. The four at present approved protein therapeutics directly target TNF and inhibit binding to its two TNF receptors. Treatment with TNF antagonists results in significant clinical responses and is generally well tolerated. Objective: Ten years of clinical experience with 1 million patients treated also revealed the limits of the available antagonists and potential therapy-associated risks, foremost being tuberculosis reactivation, but also neurologic and hematologic events, and even malignancies. These findings ask for improvement of established therapies. Method: We here review published literature on strategies interfering with TNF action and provide an overview of the now approved antagonists of TNF action as well as new reagents under development. Conclusion: Clinical experience with approved TNF antagonists shows that there is a dem...Keywords
This publication has 71 references indexed in Scilit:
- TNFα blockade in human diseases: Mechanisms and future directionsClinical Immunology, 2008
- TNF signaling inhibition in the CNS: implications for normal brain function and neurodegenerative diseaseJournal of Neuroinflammation, 2008
- Certolizumab pegol, a monthly subcutaneously administered Fc-free anti-TNFα, improves health-related quality of life in patients with moderate to severe Crohn’s diseaseInternational Journal of Colorectal Disease, 2007
- Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritisAnnals of the Rheumatic Diseases, 2007
- AKT/PKB Signaling: Navigating DownstreamCell, 2007
- TNF-α regulates myogenesis and muscle regeneration by activating p38 MAPKAmerican Journal of Physiology-Cell Physiology, 2007
- Falling into TRAPS – receptor misfolding in the TNF receptor 1-associated periodic fever syndromeArthritis Research & Therapy, 2007
- SPPL2a and SPPL2b promote intramembrane proteolysis of TNFα in activated dendritic cells to trigger IL-12 productionNature Cell Biology, 2006
- Anti-TNF Antibody Therapy in Rheumatoid Arthritis and the Risk of Serious Infections and MalignanciesJAMA, 2006
- Tumor necrosis factor signalingCell Death & Differentiation, 2003